Back to search

Article

Oral Gene III <sup>®</sup> L-Ergothioneine Capsules in Women with Suboptimal Ovarian Reserve: A Single-Center, Open-Label, Self-Controlled Pilot Study of Ovarian Reserve Markers, Endocrine Profiles, and Reproductive Aging-Related Symptoms

2026-04-04

Abstract excerpt

<h4>Purpose</h4> To evaluate the efficacy and safety of oral L-ergothioneine (EGT) in improving ovarian reserve and clinical symptoms in women with suboptimal ovarian function. As a proof-of-concept study, we explored correlations between hormonal shifts and symptom amelioration. <h4>Methods</h4> This single-center, open-label trial enrolled 40 women (aged 35–45 years) experiencing age-related reproductive decli...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fd4d2886-acb4-5652-a2d6-630e052e0fd6
DOI
10.64898/2026.04.02.26350093
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Oral Gene III <sup>®</sup> L-Ergothioneine Capsules in Women with Suboptimal Ovarian Reserve: A Single-Center, Open-Label, Self-Controlled Pilot Study of Ovarian Reserve Markers, Endocrine Profiles, and Reproductive Aging-Related SymptomsDOI 10.64898/2026.04.02.26350093
Select a neighboring publication to make it the new centre.